OncoK9 – The CANDiD Study: Summary | PetDx®

OncoK9 – The CANDiD Study: Summary

Clinical Validation of OncoK9, a Blood-Based Multi-Cancer Early Detection “Liquid Biopsy” Test for Dogs




The CANcer Detection in Dogs (CANDiD) study, an international, multi-center clinical study, was designed to validate the performance of OncoK9–a novel MCED test for dogs using next-generation sequencing (NGS) of blood-derived DNA.

The study was performed on blood samples collected prospectively from more than 1,000 client-owned dogs at more than 40 clinical sites across the United States, Canada, Brazil, the Netherlands, France, and Hong Kong between 2019 and 2021. The results demonstrated the test’s ability to detect 30 different types of canine cancer, with sensitivity of 85.4% for three of the most aggressive canine cancers (lymphoma, hemangiosarcoma and osteosarcoma) and overall sensitivity of 54.7%, at a specificity of 98.5% (corresponding to a false positive rate of just 1.5%).

Join the Revolution in Early Cancer Detection for Dogs

If you are ready to add the OncoK9 multi-cancer early detection test to your veterinary practice, we would love to hear from you.